In recent trading, shares of Quest Diagnostics, Inc. (Symbol: DGX) have crossed above the average analyst 12-month target price of $159.00, changing hands for $160.14/share. When a stock reaches the ...
CEO Jim Davis reported a nearly 15% revenue growth for Q4, including 5% organic growth, and close to 7% revenue growth for the full year, supported by eight acquisitions. He highlighted the Advanced ...
CEO Dwight Egan highlighted the development advancements of the Co-Dx PCR testing platform, including its low-cost, rapid, and easy-to-use features. The company withdrew its initial FDA 510(k) ...
In recent trading, shares of Quest Diagnostics, Inc. (Symbol: DGX) have crossed above the average analyst 12-month target price of $146.10, changing hands for $146.42/share. When a stock reaches the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback